Lineage Cell Therapeutics Inc (LCTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Lineage Cell Therapeutics Inc stock (LCTX) is currently trading at $1.48. Lineage Cell Therapeutics Inc PS ratio (Price-to-Sales) is 25.16. Analyst consensus price target for LCTX is $4.33. WallStSmart rates LCTX as Sell.
- LCTX PE ratio analysis and historical PE chart
- LCTX PS ratio (Price-to-Sales) history and trend
- LCTX intrinsic value — DCF, Graham Number, EPV models
- LCTX stock price prediction 2025 2026 2027 2028 2029 2030
- LCTX fair value vs current price
- LCTX insider transactions and insider buying
- Is LCTX undervalued or overvalued?
- Lineage Cell Therapeutics Inc financial analysis — revenue, earnings, cash flow
- LCTX Piotroski F-Score and Altman Z-Score
- LCTX analyst price target and Smart Rating
Lineage Cell Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Lineage Cell Therapeutics Inc (LCTX) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Lineage Cell Therapeutics Inc (LCTX) Key Strengths (1)
Revenue surging 130.40% year-over-year
Supporting Valuation Data
Lineage Cell Therapeutics Inc (LCTX) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Very expensive relative to growth, significant premium
Very expensive at 25.2x annual revenue
Very expensive at 8.1x book value
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 41.60%
Supporting Valuation Data
Lineage Cell Therapeutics Inc (LCTX) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 130.40%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, PEG Ratio. Some valuation metrics including PEG Ratio (10.64), Price/Sales (25.16), Price/Book (8.11) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -105.30%, Operating Margin at -99.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -105.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 130.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LCTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LCTX's Price-to-Sales ratio of 25.16x trades at a deep discount to its historical average of 316.81x (1th percentile). The current valuation is 97% below its historical high of 937.98x set in Nov 2010, and 3% above its historical low of 24.53x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~40.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Lineage Cell Therapeutics Inc (LCTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Lineage Cell Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 15M with 130% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 130% YoY, reaching 15M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.12 indicates a conservative balance sheet with 40M in cash.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Lineage Cell Therapeutics Inc maintain 130%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.76, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Lineage Cell Therapeutics Inc.
Bottom Line
Lineage Cell Therapeutics Inc is a high-conviction growth story with revenue accelerating at 130% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Lineage Cell Therapeutics Inc(LCTX)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.